Akebia Therapeutics Inc — Quarterly Financial Statistics (NASDAQ:AKBA) | MetaTrader

Open full chart

Financials

Overview Estratto Conto Statistics

Quarterly Annual

Cash from operating activities 4.47 M13.59 M-4.83 M28.11 M31.13 M 67.99 M Cash from investing activities 2 000154 K-126 K21 K7.88 M 7.93 M Cash from financing activities 22.32 M74.94 M1.72 M1.11 M-4.85 M 72.93 M Free cash flow 4.46 M13.57 M-4.96 M28.03 M31.06 M 67.7 M

Notizie

Akebia Therapeutics nomina Philip Vickers nel consiglio di amministrazione

Akebia Therapeutics, Inc. (AKBA) Presents at Leerink Global Healthcare Conference 2026 Transcript

Akebia alla Conferenza Leerink: focus strategico su Vafseo

Akebia at Leerink Conference: Strategic Focus on Vafseo and Pipeline

3 Best Stocks to Buy Today with 125%+ Upside, 2/27/2026, According to Top Analysts - TipRanks.com

Ardelyx (ARDX) Reports Break-Even Earnings for Q4

Akebia Therapeutics, Inc. (AKBA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

Akebia Therapeutics firma un nuovo contratto di locazione per la sede e modifica gli accordi di liquidazione dei dirigenti

Akebia Therapeutics signs new headquarters lease and amends executive severance agreements

Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts (NASDAQ:AKBA)

Akebia riporta il primo paziente dosato nella sperimentazione per malattie renali rare

Akebia reports first patient dosed in rare kidney disease trial